Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | Midostaurin and quizartinib: improving survival and day-to-day life in AML

Alexander Perl • 12 Sep 2018
SOHO 2018
Acute Myeloid Leukemia Leukemia Midostaurin Quizartinib

Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, discusses the effectiveness of drugs currently on the market to treat acute myeloid leukemia (AML) at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX. Dr Perl explains how the FLT3 inhibitors midostaurin and quizartinib have improved the overall survival of AML patients, and protect against relapse better than standard therapy. With tolerable side effects, he excitedly disccusses the the future of AML treatments which do not affect the patient’s day to day life.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Alexander Perl

Does the choice of FLT3 inhibitor matter in FLT3-mutated AML?
13:34
Does the choice of FLT3 inhibitor matter in FLT3-mutated AML?
Alexander Perl • 19 Sep 2026
Targeting FLT3-mutant AML: frontline strategy, MRD-guided transplant, and RAS-targeted approaches
12:28
Targeting FLT3-mutant AML: frontline strategy, MRD-guided transplant, and RAS-targeted approaches
Alexander Perl et al. • 20 Sep 2026
The VICEROY study: VEN/AZA/GILT in newly diagnosed FLT3-mutated AML
2:39
The VICEROY study: VEN/AZA/GILT in newly diagnosed FLT3-mutated AML
Alexander Perl • 5 Dec 2025
Optimizing therapy and extending survival in AML: balancing efficacy and toxicity
1:46
Optimizing therapy and extending survival in AML: balancing efficacy and toxicity
Alexander Perl • 5 Sep 2025

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals